R-IMPP is a small molecule inhibitor that suppresses PCSK9 protein synthesis, thereby upregulating hepatic LDL receptor levels and enhancing LDL cholesterol uptake in hepatoma cell models. This mechanism, which does not affect transferrin secretion, makes it a valuable research tool for studying lipid metabolism and potential therapeutic strategies for hypercholesterolemia in both in vitro and in vivo contexts.